BAX - Earnings announcements

Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis1,2 U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03); adjusted diluted EPS from continuing operations of $0.36 Reiterates full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2026. "Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution," said Andrew Hider, president and CEO. "Although more wo

Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everyw

Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and eve

Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company's focus to drive continuous improvement and sustainable growth and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025. "I joined Baxter because it's a global healthcare leader – an iconic brand with an

Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its third-quarter 2025 financial results on Thursday, October 30, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156235 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywh

Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2025 financial results on Thursday, July 31, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I156238 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everywhere it is g

First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2025 financial results on Thursday, May 1, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I763359 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on B

Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceeding the company's previously issued guidance1 Fourth-quarter U.S. GAAP2 diluted earnings per share (EPS) (loss) from continuing operations of ($0.95); adjusted diluted EPS from continuing operations of $0.58, exceeding the company's previously issued guidance Full-year sales from continuing operations of $10.64 billion increased 3% on both a reported and constant currency basis, exceeding the company's previously issued guidance Full-year U.S. GAAP diluted EPS (loss) from continuing operations of ($0.64); adjusted diluted EPS from continuing ope

José (Joe) E. Almeida to retire as Chair, President and Chief Executive Officer Lead Independent Director Brent Shafer appointed Chair and Interim CEO Board has initiated a comprehensive search to select full-time replacement Heather Knight appointed Chief Operating Officer Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025. The Baxter Board of Directors has appointed lead independent director Brent Shafer as chair and interim CEO and

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's lea

Baxter third-quarter 2024 sales totaled $3.85 billion1 Third-quarter total Baxter U.S. GAAP2 diluted earnings per share (EPS) were $0.271; adjusted total Baxter diluted EPS were $0.801, exceeding the company's previously issued guidance Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis3, reflecting growth across all segments4 Third-quarter U.S. GAAP diluted EPS from continuing operations were $0.12; adjusted continuing operations EPS were $0.49 Baxter continues to make significant progress restoring production at its North Cove facility following the unprecedented impact of Hurricane Helene in western North C

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portf

Second-quarter sales from continuing operations of $3.81 billion increased 3% on a reported basis and 4% on a constant currency basis, exceeding the company's previously issued guidance and delivering constant currency growth across all segments1 Second-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were ($0.62) and adjusted diluted EPS from continuing operations were $0.68, exceeding the company's previously issued guidance Baxter increases its full-year sales guidance and now expects sales growth of approximately 3% on both a reported and constant currency basis Baxter increases its full-year adjusted diluted EPS guidance and now expects adjusted

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I898552708 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leadi

First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company's previously issued guidance1 First-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were $0.07 and adjusted diluted EPS from continuing operations were $0.65, exceeding the company's previously issued guidance Baxter now expects full-year 2024 sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis Baxter now expects full-year adjusted EPS of $2.88 to $2.981 Recent U.S. FDA clearance of Novum IQ large volume infusion pump and Dose IQ Safety Software advanc

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading por

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the "Amended Agreement") with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. ("Baxter") (NYSE:BAX), originally entered into in February 2020. Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the blood

Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of $0.14 and adjusted diluted EPS from continuing operations of $0.88 Full-year sales from continuing operations of $14.81 billion increased 2% on a reported basis and 3% on a constant currency basis Full-year U.S. GAAP diluted EPS (loss) from continuing operations of ($0.15) and adjusted diluted EPS from continuing operations of $2.60 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's lead

Third-quarter revenue from continuing operations of $3.71 billion increased 3% on a reported basis and 2% on a constant currency basis, ahead of the company's previously issued guidance1 Third-quarter U.S. GAAP earnings per share (EPS) from continuing operations of $0.09; adjusted EPS from continuing operations of $0.68 exceeded guidance Third-quarter U.S. GAAP EPS in the aggregate (including discontinued operations) totaled $4.93; adjusted EPS in the aggregate (including discontinued operations) of $0.82 exceeded guidance Starting this quarter, Baxter is reporting performance according to four verticalized business segments, reflecting the strategic realignment announced in Jan.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2023 financial results on Thursday, November 2, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leadi

Second-quarter revenues increased 3% on a reported basis and 4% on a constant currency basis, ahead of the company's previously issued guidance1 Second-quarter U.S. GAAP earnings (loss) per share (EPS) (including discontinued operations) of ($0.28); adjusted EPS (including discontinued operations) of $0.66 Second-quarter U.S. GAAP EPS from continuing operations of ($0.39); adjusted EPS from continuing operations of $0.55  Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023. "Baxter's second-quarter performance reflects ongoing solid demand for our diverse, durable portfolio of medically essential products," said Jo

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2023 financial results on Thursday, July 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/XvgzXupv to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading

First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.09; Adjusted EPS totaled $0.59 Baxter expects full-year 2023 sales growth of 1% to 2% on a reported basis and ~1% on a constant currency basis Baxter expects full-year U.S. GAAP EPS of $1.16 to $1.31 and adjusted EPS of $2.85 to $3.00 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023. "Baxter's performance in the first quarter reflects sustained demand for our medically essential products amid a stabilizing macroeconomic climate and he

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/WhpPxesO to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading

Fourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) of $0.36 and adjusted diluted EPS of $0.88 Full-year sales of $15.1 billion increased 18% on a reported basis, 23% on a constant currency basis and 2% on an operational basis Full-year U.S. GAAP diluted EPS (loss) of ($4.83) and adjusted diluted EPS of $3.50 Company provides update on previously announced actions to improve operational efficiency through streamlined operating model while positioning for proposed spinoff of Renal Care and Acute Therapies businesses Baxter International Inc

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2022 financial results on Thursday, February 9, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading

Planning to spin off the Renal Care and Acute Therapies global business units into an independent, publicly traded company in the next 12-18 months Simplifying operating model and manufacturing footprint to drive strategic clarity, improve operational efficiencies and accelerate future growth Exploring strategic alternatives for BioPharma Solutions business to further enhance focus and improve capital structure Hosting investor call today at 7:30 a.m. CST  Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, acceler

Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis1 Third-quarter U.S. GAAP earnings (loss) per share (EPS) were ($5.83); Adjusted EPS totaled $0.82 Third-quarter results reflect impairment charges of $3.1 billion related to Baxter's December 2021 Hillrom acquisition, primarily reflecting rising interest rates and broad declines in equity valuations Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2022. "Baxter's wide-ranging product portfolio is fundamental to healthcare globally, and at the heart of our sustained success ove

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2022 financial results on Thursday, October 27, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading

Second-quarter revenue of $3.75 billion increased 21% on a reported basis, 26% on a constant currency basis and 3% on an operational basis1 Second-quarter U.S. GAAP earnings per share (EPS) totaled $0.50; Adjusted EPS totaled $0.87 Baxter now expects full-year 2022 sales growth to advance in the high teens on a reported basis, mid-20s on a constant currency basis and 2% to 3% on an operational basis Baxter now expects full-year U.S. GAAP EPS of $1.82 to $1.92 and adjusted EPS of $3.60 to $3.70 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2022. "Baxter's diverse, durable portfolio of essential healthcare products po

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading po

First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93 Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency basis and approximately 3% on an operational basis Baxter expects full-year U.S. GAAP EPS of $2.35 to $2.43 and adjusted EPS of $4.12 to $4.20 The company is hosting an Investor Conference on May 25, 2022, to provide additional details regarding its strategic outlook and updated long-term financial guidance Baxter International Inc. (NYSE:BAX),

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2022 financial results on Thursday, April 28, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading po

Fourth-quarter sales of $3.5 billion increased 10% on a reported basis, 12% on a constant currency basis and 4% on an operational basis1 Fourth-quarter U.S. GAAP earnings per share (EPS) of $0.47 and adjusted EPS of $1.04 Full-year revenue of $12.8 billion increased 10% on a reported basis, 7% on a constant currency basis and 5% on an operational basis Full-year U.S. GAAP EPS of $2.53 and adjusted EPS of $3.61 Baxter's acquisition of Hillrom positions company to accelerate top- and bottom-line performance and drive innovation in connected care solutions focused on enhancing clinical outcomes for patients and improving workflow efficiency for customers Baxter International Inc. (N

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2021 financial results on Thursday, February 17, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3168996 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare p

Third-quarter revenue of $3.2 billion increased 9% on a reported basis, 7% on a constant currency basis and 6% on an operational basis1 Third-quarter U.S. GAAP earnings per share (EPS) of $0.89 increased 29%; Adjusted EPS of $1.02 increased 23% Baxter expects full-year 2021 sales growth of 7% to 8% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis Baxter now expects full-year U.S. GAAP EPS of $2.82 to $2.86 and adjusted EPS of $3.58 to $3.62 Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021. "Baxter's essential products, diverse portfolio and global sca

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients and caregive